GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Avantor Inc (NYSE:AVTR) » Definitions » EV-to-EBIT

AVTR (Avantor) EV-to-EBIT : 12.58 (As of Jul. 02, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Avantor EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Avantor's Enterprise Value is $13,277 Mil. Avantor's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $1,056 Mil. Therefore, Avantor's EV-to-EBIT for today is 12.58.

The historical rank and industry rank for Avantor's EV-to-EBIT or its related term are showing as below:

AVTR' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.36   Med: 30.1   Max: 63.77
Current: 12.58

During the past 9 years, the highest EV-to-EBIT of Avantor was 63.77. The lowest was 11.36. And the median was 30.10.

AVTR's EV-to-EBIT is ranked better than
69.48% of 462 companies
in the Medical Devices & Instruments industry
Industry Median: 19.84 vs AVTR: 12.58

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Avantor's Enterprise Value for the quarter that ended in Mar. 2025 was $14,838 Mil. Avantor's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $1,056 Mil. Avantor's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 7.11%.


Avantor EV-to-EBIT Historical Data

The historical data trend for Avantor's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avantor EV-to-EBIT Chart

Avantor Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only 59.32 34.44 18.03 29.80 16.91

Avantor Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.77 26.96 35.40 16.91 14.06

Competitive Comparison of Avantor's EV-to-EBIT

For the Medical Instruments & Supplies subindustry, Avantor's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avantor's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avantor's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Avantor's EV-to-EBIT falls into.


;
;

Avantor EV-to-EBIT Calculation

Avantor's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=13276.501/1055.7
=12.58

Avantor's current Enterprise Value is $13,277 Mil.
Avantor's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,056 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avantor  (NYSE:AVTR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Avantor's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=1055.7/14838.115
=7.11 %

Avantor's Enterprise Value for the quarter that ended in Mar. 2025 was $14,838 Mil.
Avantor's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,056 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avantor EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Avantor's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Avantor Business Description

Traded in Other Exchanges
Address
100 Matsonford Road, Suite 200, Building One, Radnor Corporate Center, Radnor, PA, USA, 19087
Avantor Inc provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment & instrumentation, Services & specialty procurement, Proprietary materials & consumables, and Third-party materials & consumables. Materials & consumables include high-purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, and education and microbiology and clinical trial kits, peristaltic pumps and fluid handling tips.
Executives
Gregory L Summe director C/O GLEN CAPITAL PARTNERS LLC, 800 SOUTH STREET, SUITE 160, WALTHAM MA 02453
Joseph R Massaro director 5725 DELPHI DRIVE, TROY MI 48098
Jonathan M Peacock director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Lan Kang director 100 MATSONFORD ROAD, RADNOR PA 19087
James Bramwell officer: EVP, Strategic Partners C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Steven W Eck officer: SVP & Chief Accounting Officer C/O CSS INDUSTRIES, INC., 450 PLYMOUTH ROAD, SUITE 300, PLYMOUTH MEETING PA 19462
Christophe Couturier officer: See Remarks 9 FOURTH AVENUE, C/O OVASCIENCE INC., CAMBRIDGE MA 02451
Benoit Gourdier officer: EVP, Biopharma Production 100 MATSONFORD ROAD, RADNOR PA 19087
Frederic Vanderhaegen officer: EVP, Europe C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Brittany Hankamer officer: EVP, Chief HR Officer 100 MATSONFORD ROAD, RADNOR PA 19087
R. Brent Jones officer: EVP, Chief Financial Officer C/O PALL CORPORATION, 25 HARBOR PARK DRIVE, PORT WASHINGTON NY 11050
Claudius Sokenu officer: EVP, Chief Legal & Compliance C/O UNISYS CORPORATION, 801 LAKEVIEW DRIVE, BLUE BELL PA 19422
Randy Lee Stone officer: EVP, Proprietary Products 974 CENTRE ROAD, CRP 730, WILMINGTON DE 19805
Gerard Brophy officer: EVP, Biopharma Production C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Kitty Sahin officer: EVP, Strategy&Corp Development 100 MATSONFORD ROAD, RADNOR PA 19087